90 related articles for article (PubMed ID: 16249028)
1. Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation.
Galimberti S; Benedetti E; Morabito F; Petrini I; Battolla B; Papineschi F; Fazzi R; Ciabatti E; Martino M; Cuzzola M; Console G; Iacopino P; Petrini M
Leuk Res; 2006 May; 30(5):529-35. PubMed ID: 16249028
[TBL] [Abstract][Full Text] [Related]
2. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.
Galimberti S; Benedetti E; Morabito F; Papineschi F; Callea V; Fazzi R; Stelitano C; Andreazzoli F; Guerrini F; Ciabatti E; Martino M; Nobile F; Iacopino P; Petrini M
Leuk Res; 2005 Aug; 29(8):961-6. PubMed ID: 15978948
[TBL] [Abstract][Full Text] [Related]
4. The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors.
Pabst C; Schirutschke H; Ehninger G; Bornhäuser M; Platzbecker U
Clin Cancer Res; 2007 May; 13(10):2916-22. PubMed ID: 17504991
[TBL] [Abstract][Full Text] [Related]
5. Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation.
Voena C; Malnati M; Majolino I; Fagà G; Montefusco V; Farina L; Santoro A; Ladetto M; Boccadoro M; Corradini P
Bone Marrow Transplant; 2003 Oct; 32(8):791-3. PubMed ID: 14520423
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of lymphocytic clone formation after stem cell transplantation and immunological reconstitution by gene fingerprinting].
Zhu P; Li J; Ma M
Zhonghua Yi Xue Za Zhi; 2000 Sep; 80(9):668-71. PubMed ID: 11798833
[TBL] [Abstract][Full Text] [Related]
8. Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting.
Galimberti S; Benedetti E; Morabito F; Fazzi R; Pacini S; Andreazzoli F; Martino M; Iacopino P; Petrini M
Transpl Immunol; 2005 Dec; 15(2):173-7. PubMed ID: 16412962
[TBL] [Abstract][Full Text] [Related]
9. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect.
Khaled Y; Mellacheruvu S; Reddy P; Peres E; Mineishi S
Bone Marrow Transplant; 2009 Sep; 44(5):325-6. PubMed ID: 19204708
[No Abstract] [Full Text] [Related]
11. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
Zeiser R; Finke J
Eur J Cancer; 2006 Jul; 42(11):1601-11. PubMed ID: 16759847
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
Kröger N; Zagrivnaja M; Schwartz S; Badbaran A; Zabelina T; Lioznov M; Ayuk F; Zander A; Fehse B
Exp Hematol; 2006 May; 34(5):688-94. PubMed ID: 16647575
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.
Le Gouill S; Milpied N; Buzyn A; De Latour RP; Vernant JP; Mohty M; Moles MP; Bouabdallah K; Bulabois CE; Dupuis J; Rio B; Gratecos N; Yakoub-Agha I; Attal M; Tournilhac O; Decaudin D; Bourhis JH; Blaise D; Volteau C; Michallet M;
J Clin Oncol; 2008 May; 26(14):2264-71. PubMed ID: 18390969
[TBL] [Abstract][Full Text] [Related]
15. Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience.
Kennedy GA; Butler J; Morton J; Hill G; Western R; Cummings J; Allison R; Durrant S
Clin Lab Haematol; 2006 Jun; 28(3):189-97. PubMed ID: 16706936
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
[TBL] [Abstract][Full Text] [Related]
17. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
18. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
19. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
20. Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation.
Lee CK; Zangari M; Fassas A; Thertulien R; Talamo G; Badros A; Cottler-Fox M; van Rhee F; Barlogie B; Tricot G
Bone Marrow Transplant; 2006 Mar; 37(5):511-5. PubMed ID: 16435020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
